Peregrine Asset Advisers, Inc. Cytom X Therapeutics, Inc. Transaction History
Peregrine Asset Advisers, Inc.
- $293 Million
- Q2 2025
A detailed history of Peregrine Asset Advisers, Inc. transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Peregrine Asset Advisers, Inc. holds 10,000 shares of CTMX stock, worth $31,900. This represents 0.01% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$31,900
Previous $6,000
266.67%
% of portfolio
0.01%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CTMX
# of Institutions
88Shares Held
123MCall Options Held
305KPut Options Held
121K-
Vr Adviser, LLC New York, NY14MShares$44.6 Million6.28% of portfolio
-
Tang Capital Management LLC San Diego, CA11.1MShares$35.3 Million1.5% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.38MShares$29.9 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.46MShares$27 Million0.69% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.08MShares$25.8 Million0.04% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $210M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...